Insys Therapeutics Inc (INSY) 51.50 $INSY
NTRR Leadership Travels to Colorado to Strike Product Testing Deals With Cannabis Farmers
Business Wire - Thu Feb 12, 4:00AM CST
Representatives from Neutra Corp. (OTCBB: NTRR) and its joint venture partner, Surface to Air Solutions (S2O2), traveled to Colorado this week seeking out new product testing partnerships with local cannabis farmers.
INSY: 51.50 (-0.66)
Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea
at Investor's Business Daily - Tue Feb 10, 10:01AM CST
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half...
CBPO: 69.12 (+0.42), BIIB: 391.66 (-0.45), INSY: 51.50 (-0.66), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)
GTSO Formulates New Acquisitions Strategy in $2.7 Billion U.S. Cannabis Industry
Business Wire - Mon Feb 09, 8:53AM CST
Green Technology Solutions, Inc. (OTCBB: GTSO) announced today that the company is beginning a new acquisitions campaign to fill out its asset portfolio with new technology products, services and innovations in the $2.7 billion U.S. cannabis industry.
INSY: 51.50 (-0.66)
NTRR Targets Colorado as Ideal Market to Test New Cannabis Cultivation Technology
Business Wire - Mon Feb 09, 8:31AM CST
Neutra Corp. (OTCBB: NTRR), a provider of innovative all-natural wellness solutions, and joint venture partner Surface to Air Solutions (S2O2) are working to build new partnerships with cannabis cultivators in Colorado to test out and demonstrate the company's suite of market-ready agricultural technologies.
INSY: 51.50 (-0.66)
NTRR Plans Bold Expansion Into New Nutraceutical Markets With Versatile Inhalation Technology
Business Wire - Thu Feb 05, 4:00AM CST
As Neutra Corp. (OTCBB: NTRR) continues to develop new nutraceutical applications for the Diamond Anvil vapor pen, the company is making plans to expose the innovative product offering to potentially lucrative new global markets beyond the legal cannabis industry.
INSY: 51.50 (-0.66)
Earth Science Tech Building A Nutrition Empire Based On High Grade CBD and Nutraceutical Retailing
ACCESSWIRE - Wed Feb 04, 8:11AM CST
WHITEFISH, MT / ACCESSWIRE / February 4, 2015 / Earth Science Tech (OTC: ETST) has been making excellent progress validating the efficacy of their proprietary CBD (cannabidiol) Rich Hemp Oil product lately via work done at the University of Central Oklahoma, carried out under the visionary eye of the university's Assistant Dean of the College of Mathematics & Science, world-renown scientist and researcher Dr. Wei R. Chen. Following up on initial preliminary testing in animal breast cancer last year, which showed that the appropriate dosages could indeed inhibit cancer cell proliferation at a significant rate, subsequent research into the product's ability to bolster the body's immune system by stimulating the production of a key cytokine (TNF-alpha, a signaling protein) in macrophages ("big eater" white blood cells that engulf and digest things like microbes and cancer cells), has now produced promising results as well.
HLF: 32.78 (-0.84), CARA: 10.96 (-0.03), INSY: 51.50 (-0.66), NATR: 14.18 (-0.04), GWPH: 78.09 (+1.70)
This Governor Just Exposed Marijuana's Greatest Weakness
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 01, 10:41AM CST
Legal grow marijuana in Colorado. Source: Flickr user Brett Levin. For decades, marijuana was a drug few would have ever supported legalizing. Between the 1960s and the mid-2000s, support for marijuana's legalization ranged from the low teens to...
INSY: 51.50 (-0.66)
NTRR Prepares to Deliver New Technologies for the Fastest Growing Industry in the U.S.
Business Wire - Wed Jan 28, 4:00AM CST
As Neutra Corp. (OTCBB: NTRR) and its partners continue to market and develop new products to serve the U.S. cannabis industry, a new report from analysts ArcView Market Research named that rapidly expanding industry as the fastest-growing in the country.
INSY: 51.50 (-0.66)
Insys Therapeutics wins US FDA's orphan drug designation for Liposomal Encapsulated Paclitaxel for ovarian cancer
M2 - Tue Jan 27, 3:27AM CST
Pharmaceutical company Insys Therapeutics (NASDAQ:INSY) reported on Monday the receipt of the US Food and Drug Administration's (FDA) orphan drug designation (ODD) for its Liposomal Encapsulated Paclitaxel (LEP) candidate for the treatment of ovarian cancer.
INSY: 51.50 (-0.66)
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Liposomal Encapsulated Paclitaxel for the Treatment of Ovarian Cancer
Marketwired - Mon Jan 26, 7:01AM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its Liposomal Encapsulated Paclitaxel (LEP) candidate for the treatment of ovarian cancer.
INSY: 51.50 (-0.66)
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part VII
Anthony Cataldo - at Seeking Alpha - Fri Jan 23, 1:56PM CST
INSY: 51.50 (-0.66), GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), LINE: 12.94 (+0.40), BAR: 29.93 (+0.49)
Insys Therapeutics Shakes Off Script Scandal
Debra Borchardt - at Seeking Alpha - Fri Jan 23, 12:02PM CST
INSY: 51.50 (-0.66)
Will Insys Therapeutics (INSY) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 7:54AM CST
Will Insys Therapeutics (INSY) Continue to Surge Higher?
INSY: 51.50 (-0.66)
Medical Marijuana Goes Wall Street
Todd Campbell, The Motley Fool - Motley Fool - Wed Jan 21, 8:02AM CST
Source: Flickr user Matthew Kenwrick . Recently, there has been a groundswell of support for medical marijuana that includes both the legalization of marijuana strains that can be grown and sold locally and increased access to FDA-approved...
INSY: 51.50 (-0.66), JPM: 59.67 (+0.10)
Marijuana Stocks 2015: What You Need to Know
Todd Campbell, The Motley Fool - Motley Fool - Tue Jan 20, 12:01PM CST
Both medical and recreational marijuana have been in the news over the past year, with changes in both social acceptance and legal status in different parts of the country. Tune in to learn what investors should know when looking at marijuana-related...
INSY: 51.50 (-0.66), JPM: 59.67 (+0.10), GWPH: 78.09 (+1.70)
This Is Where The Investment Opportunity Is Right Now In Cannabis
Small Cap Reporter - at Seeking Alpha - Tue Jan 20, 11:25AM CST
INSY: 51.50 (-0.66), GWPH: 78.09 (+1.70)
New Provisional Patents Filed for Pharmaceutical Cannabidiol (CBD) Formulation Consisting of Ibuprofen & CBD Compounds Aimed At Treating Pain
PR Newswire - Tue Jan 20, 7:45AM CST
Cannabinoids, including cannabidiol (CBD) are an essential part of hemp and cannabis medicine that consist of aromatic compounds that work in concert to promote healing and well being through the consistent symptom relief. Leading Cannabidiol Development Solutions Providers in focus today are: Stevia Corp. (OTC: STEV), GW Pharmaceuticals plc (NASDAQ: GWPH), INSYS Therapeutics, inc. (NASDAQ: INSY), CannaVEST Corp. (OTC: CANV) and American Green, Inc. (OTC: ERBB)
JNJ: 99.62 (+1.18), INSY: 51.50 (-0.66), GWPH: 78.09 (+1.70), PFE: 34.64 (-0.23), CBD: 32.02 (-0.50)
5 Tiny Biotech Stocks to Own in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 17, 5:51AM CST
Biotech stocks are among the market's riskiest, but investors willing to accept the potential for pipeline failure might consider owning these five small-cap biotech stocks in 2015. All five have intriguing therapies in late-stage clinical trials,...
JNJ: 99.62 (+1.18), INSY: 51.50 (-0.66), PTLA: 34.96 (+3.13), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), OPHT: 51.11 (+0.12), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16), XLRN: 38.02 (+0.07)
Are There Any Marijuana Stocks to Buy in 2015?
Motley Fool Staff - Motley Fool - Fri Jan 16, 12:04PM CST
Source: Flickr user Carlos Gracia. Perhaps nothing caught the eyes of speculative investors more than marijuana stocks in 2014, but just because marijuana stocks put up significant returns last year doesn't mean that they can do it again in 2015....
INSY: 51.50 (-0.66), GWPH: 78.09 (+1.70)
NTRR Leadership Travels to Colorado to Strike Product Testing Deals With Cannabis Farmers
Business Wire - Thu Feb 12, 4:00AM CST
Representatives from Neutra Corp. (OTCBB: NTRR) and its joint venture partner, Surface to Air Solutions (S2O2), traveled to Colorado this week seeking out new product testing partnerships with local cannabis farmers.
INSY: 51.50 (-0.66)
Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea
at Investor's Business Daily - Tue Feb 10, 10:01AM CST
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half...
CBPO: 69.12 (+0.42), BIIB: 391.66 (-0.45), INSY: 51.50 (-0.66), PCYC: 163.28 (+0.23), BMRN: 100.76 (+1.98), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), CELG: 115.88 (+0.16)
GTSO Formulates New Acquisitions Strategy in $2.7 Billion U.S. Cannabis Industry
Business Wire - Mon Feb 09, 8:53AM CST
Green Technology Solutions, Inc. (OTCBB: GTSO) announced today that the company is beginning a new acquisitions campaign to fill out its asset portfolio with new technology products, services and innovations in the $2.7 billion U.S. cannabis industry.
INSY: 51.50 (-0.66)
NTRR Targets Colorado as Ideal Market to Test New Cannabis Cultivation Technology
Business Wire - Mon Feb 09, 8:31AM CST
Neutra Corp. (OTCBB: NTRR), a provider of innovative all-natural wellness solutions, and joint venture partner Surface to Air Solutions (S2O2) are working to build new partnerships with cannabis cultivators in Colorado to test out and demonstrate the company's suite of market-ready agricultural technologies.
INSY: 51.50 (-0.66)
NTRR Plans Bold Expansion Into New Nutraceutical Markets With Versatile Inhalation Technology
Business Wire - Thu Feb 05, 4:00AM CST
As Neutra Corp. (OTCBB: NTRR) continues to develop new nutraceutical applications for the Diamond Anvil vapor pen, the company is making plans to expose the innovative product offering to potentially lucrative new global markets beyond the legal cannabis industry.
INSY: 51.50 (-0.66)
Earth Science Tech Building A Nutrition Empire Based On High Grade CBD and Nutraceutical Retailing
ACCESSWIRE - Wed Feb 04, 8:11AM CST
WHITEFISH, MT / ACCESSWIRE / February 4, 2015 / Earth Science Tech (OTC: ETST) has been making excellent progress validating the efficacy of their proprietary CBD (cannabidiol) Rich Hemp Oil product lately via work done at the University of Central Oklahoma, carried out under the visionary eye of the university's Assistant Dean of the College of Mathematics & Science, world-renown scientist and researcher Dr. Wei R. Chen. Following up on initial preliminary testing in animal breast cancer last year, which showed that the appropriate dosages could indeed inhibit cancer cell proliferation at a significant rate, subsequent research into the product's ability to bolster the body's immune system by stimulating the production of a key cytokine (TNF-alpha, a signaling protein) in macrophages ("big eater" white blood cells that engulf and digest things like microbes and cancer cells), has now produced promising results as well.
HLF: 32.78 (-0.84), CARA: 10.96 (-0.03), INSY: 51.50 (-0.66), NATR: 14.18 (-0.04), GWPH: 78.09 (+1.70)
This Governor Just Exposed Marijuana's Greatest Weakness
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 01, 10:41AM CST
Legal grow marijuana in Colorado. Source: Flickr user Brett Levin. For decades, marijuana was a drug few would have ever supported legalizing. Between the 1960s and the mid-2000s, support for marijuana's legalization ranged from the low teens to...
INSY: 51.50 (-0.66)
NTRR Prepares to Deliver New Technologies for the Fastest Growing Industry in the U.S.
Business Wire - Wed Jan 28, 4:00AM CST
As Neutra Corp. (OTCBB: NTRR) and its partners continue to market and develop new products to serve the U.S. cannabis industry, a new report from analysts ArcView Market Research named that rapidly expanding industry as the fastest-growing in the country.
INSY: 51.50 (-0.66)
Insys Therapeutics wins US FDA's orphan drug designation for Liposomal Encapsulated Paclitaxel for ovarian cancer
M2 - Tue Jan 27, 3:27AM CST
Pharmaceutical company Insys Therapeutics (NASDAQ:INSY) reported on Monday the receipt of the US Food and Drug Administration's (FDA) orphan drug designation (ODD) for its Liposomal Encapsulated Paclitaxel (LEP) candidate for the treatment of ovarian cancer.
INSY: 51.50 (-0.66)
Insys Therapeutics Receives FDA Orphan Drug Designation for Its Liposomal Encapsulated Paclitaxel for the Treatment of Ovarian Cancer
Marketwired - Mon Jan 26, 7:01AM CST
Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its Liposomal Encapsulated Paclitaxel (LEP) candidate for the treatment of ovarian cancer.
INSY: 51.50 (-0.66)
12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part VII
Anthony Cataldo - at Seeking Alpha - Fri Jan 23, 1:56PM CST
INSY: 51.50 (-0.66), GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06), LINE: 12.94 (+0.40), BAR: 29.93 (+0.49)
Insys Therapeutics Shakes Off Script Scandal
Debra Borchardt - at Seeking Alpha - Fri Jan 23, 12:02PM CST
INSY: 51.50 (-0.66)
Will Insys Therapeutics (INSY) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 7:54AM CST
Will Insys Therapeutics (INSY) Continue to Surge Higher?
INSY: 51.50 (-0.66)
Medical Marijuana Goes Wall Street
Todd Campbell, The Motley Fool - Motley Fool - Wed Jan 21, 8:02AM CST
Source: Flickr user Matthew Kenwrick . Recently, there has been a groundswell of support for medical marijuana that includes both the legalization of marijuana strains that can be grown and sold locally and increased access to FDA-approved...
INSY: 51.50 (-0.66), JPM: 59.67 (+0.10)
Marijuana Stocks 2015: What You Need to Know
Todd Campbell, The Motley Fool - Motley Fool - Tue Jan 20, 12:01PM CST
Both medical and recreational marijuana have been in the news over the past year, with changes in both social acceptance and legal status in different parts of the country. Tune in to learn what investors should know when looking at marijuana-related...
INSY: 51.50 (-0.66), JPM: 59.67 (+0.10), GWPH: 78.09 (+1.70)
This Is Where The Investment Opportunity Is Right Now In Cannabis
Small Cap Reporter - at Seeking Alpha - Tue Jan 20, 11:25AM CST
INSY: 51.50 (-0.66), GWPH: 78.09 (+1.70)
New Provisional Patents Filed for Pharmaceutical Cannabidiol (CBD) Formulation Consisting of Ibuprofen & CBD Compounds Aimed At Treating Pain
PR Newswire - Tue Jan 20, 7:45AM CST
Cannabinoids, including cannabidiol (CBD) are an essential part of hemp and cannabis medicine that consist of aromatic compounds that work in concert to promote healing and well being through the consistent symptom relief. Leading Cannabidiol Development Solutions Providers in focus today are: Stevia Corp. (OTC: STEV), GW Pharmaceuticals plc (NASDAQ: GWPH), INSYS Therapeutics, inc. (NASDAQ: INSY), CannaVEST Corp. (OTC: CANV) and American Green, Inc. (OTC: ERBB)
JNJ: 99.62 (+1.18), INSY: 51.50 (-0.66), GWPH: 78.09 (+1.70), PFE: 34.64 (-0.23), CBD: 32.02 (-0.50)
5 Tiny Biotech Stocks to Own in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 17, 5:51AM CST
Biotech stocks are among the market's riskiest, but investors willing to accept the potential for pipeline failure might consider owning these five small-cap biotech stocks in 2015. All five have intriguing therapies in late-stage clinical trials,...
JNJ: 99.62 (+1.18), INSY: 51.50 (-0.66), PTLA: 34.96 (+3.13), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), OPHT: 51.11 (+0.12), REGN: 402.40 (+0.66), NVS: 102.20 (-0.17), CELG: 115.88 (+0.16), XLRN: 38.02 (+0.07)
Are There Any Marijuana Stocks to Buy in 2015?
Motley Fool Staff - Motley Fool - Fri Jan 16, 12:04PM CST
Source: Flickr user Carlos Gracia. Perhaps nothing caught the eyes of speculative investors more than marijuana stocks in 2014, but just because marijuana stocks put up significant returns last year doesn't mean that they can do it again in 2015....
INSY: 51.50 (-0.66), GWPH: 78.09 (+1.70)
